NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple Myeloma [ATAC-seq]
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 22 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Samples
- 22 samples: 8 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple MyelomaBlood · 2026
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE328215_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1454357 and SRA study SRP692363. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 16 samples.
How we read this: 8 replicated groups read from 22 sample titles; they account for 16 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9675118 KMS11_DMSO_Dup1_Day10 KMS11_DMSO_Dup1_Day
- GSM9675119 KMS11_DMSO_Dup1_Day4 KMS11_DMSO_Dup1_Day
- GSM9675120 KMS11_DMSO_Dup2_Day10 KMS11_DMSO_Dup2_Day
- GSM9675121 KMS11_DMSO_Dup2_Day4 KMS11_DMSO_Dup2_Day
- GSM9675122 KMS11_Dup1_Day0
- GSM9675123 KMS11_Dup2_Day0
- GSM9675124 KMS11_NSD2LDD_Dup1_Day10 KMS11_NSD2LDD_Dup1_Day
- GSM9675125 KMS11_NSD2LDD_Dup1_Day4 KMS11_NSD2LDD_Dup1_Day
- GSM9675126 KMS11_NSD2LDD_Dup2_Day10 KMS11_NSD2LDD_Dup2_Day
- GSM9675127 KMS11_NSD2LDD_Dup2_Day4 KMS11_NSD2LDD_Dup2_Day
- GSM9675128 KMS11_TKO_Dup1_Day0
- GSM9675129 KMS11_TKO_Dup2_Day0
- GSM9675130 KMS34_DMSO_Dup1_Day10 KMS34_DMSO_Dup1_Day
- GSM9675131 KMS34_DMSO_Dup1_Day4 KMS34_DMSO_Dup1_Day
- GSM9675132 KMS34_DMSO_Dup2_Day10 KMS34_DMSO_Dup2_Day
- GSM9675133 KMS34_DMSO_Dup2_Day4 KMS34_DMSO_Dup2_Day
- GSM9675134 KMS34_Dup1_Day0
- GSM9675135 KMS34_Dup2_Day0
- GSM9675136 KMS34_NSD2LDD_Dup1_Day10 KMS34_NSD2LDD_Dup1_Day
- GSM9675137 KMS34_NSD2LDD_Dup1_Day4 KMS34_NSD2LDD_Dup1_Day
- GSM9675138 KMS34_NSD2LDD_Dup2_Day10 KMS34_NSD2LDD_Dup2_Day
- GSM9675139 KMS34_NSD2LDD_Dup2_Day KMS34_NSD2LDD_Dup2_Day
- GSE328217 NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple Myeloma 46 samples shares nsd2, degradation, remediates, oncogenic, cistrome, multiple, myeloma
- GSE328216 NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple Myeloma [RNA-seq] 24 samples shares nsd2, degradation, remediates, oncogenic, cistrome, multiple, myeloma
- GSE294275 Transcriptional analysis of direct NSD2 target genes in t(4;14) multiple myeloma reveals H3K36me2-dependent regulation and H3K27me3 antagonism [CUT&TAG] 40 samples shares nsd2, multiple, myeloma
- GSE230466 Aberrant non-canonical NF-κB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma [ChIP-seq] 61 samples shares oncogenic, multiple, myeloma
- GSE274846 p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma (MM1S_SOC) 45 samples shares oncogenic, multiple, myeloma
- GSE245149 NSD2 Overexpression in Myeloma Enhances Dependency on Mitochondrial High Energy Phosphate Transport Facilitated by Adenylate Kinase 2 [AS_RS] 12 samples shares nsd2, myeloma
- GSE244183 Degradation of Ikaros prevents epigenetic progression of T cell exhaustion in novel antigen-specific assay [bulk ATAC-seq] 11 samples shares degradation, atac-seq
- GSE301713 Mezigdomide reverses T cell exhaustion through degradation of Aiolos/Ikaros and reinvigoration of cytokine production pathways [ATAC-seq] 9 samples shares degradation, atac-seq
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.